5,477
edits
Semaglutide and cardiovascular risk: Difference between revisions
no edit summary
(Created page with "{{Short description|Semaglutide and cardiovascular risk, Wegovy heart-risk reduction, SELECT trial, Ozempic cardiovascular data, heart failure, kidney outcomes, and W8MD medical weight loss care}} {{DISPLAYTITLE:Semaglutide and cardiovascular risk}} __NOTOC__ {{Infobox drug | drug_name = Semaglutide and cardiovascular risk | image = 250px | caption = Semaglutide has evidence for reducing cardiovascular risk in selected patients wit...") |
No edit summary |
||
| Line 5: | Line 5: | ||
{{Infobox drug | {{Infobox drug | ||
| drug_name = Semaglutide and cardiovascular risk | | drug_name = Semaglutide and cardiovascular risk | ||
| image = | | image = | ||
| caption = [[Semaglutide]] has evidence for reducing cardiovascular risk in selected patients with [[obesity]], [[overweight]], [[type 2 diabetes]], established [[cardiovascular disease]], and related cardiometabolic conditions. | | caption = [[Semaglutide]] has evidence for reducing cardiovascular risk in selected patients with [[obesity]], [[overweight]], [[type 2 diabetes]], established [[cardiovascular disease]], and related cardiometabolic conditions. | ||
| tradename = [[Wegovy]], [[Ozempic]], [[Rybelsus]] | | tradename = [[Wegovy]], [[Ozempic]], [[Rybelsus]] | ||
| Line 71: | Line 71: | ||
[[File:W8MD-Team.jpg|thumb|right|350px|[[W8MD Weight Loss, Sleep and MedSpa]] helps patients with semaglutide evaluation, cardiovascular-risk focused weight loss, nutrition, sleep apnea screening, and long-term maintenance.]] | [[File:W8MD-Team.jpg|thumb|right|350px|[[W8MD Weight Loss, Sleep and MedSpa]] helps patients with semaglutide evaluation, cardiovascular-risk focused weight loss, nutrition, sleep apnea screening, and long-term maintenance.]] | ||
[[File:Woman-losing-weight.jpeg|thumb|right|350px|Cardiovascular risk reduction with semaglutide works best when medication is combined with nutrition, physical activity, blood pressure control, sleep optimization, and medical follow-up.]] | [[File:Woman-losing-weight.jpeg|thumb|right|350px|Cardiovascular risk reduction with semaglutide works best when medication is combined with nutrition, physical activity, blood pressure control, sleep optimization, and medical follow-up.]] | ||
==Overview== | ==Overview== | ||
| Line 242: | Line 237: | ||
==Semaglutide and stroke risk== | ==Semaglutide and stroke risk== | ||
[[File:Before-and-after-weight-loss.jpeg|thumb|right|350px|Before-and-after weight loss image. Individual semaglutide and cardiovascular-risk outcomes vary and require medical supervision.]] | |||
[[File:Body mass index chart.svg|thumb|right|300px|[[Body mass index]] is one tool used to assess obesity-related cardiovascular risk and medication eligibility.]] | |||
[[File:Obesity-waist circumference.svg|thumb|right|300px|[[Waist circumference]], [[central obesity]], and [[visceral fat]] are strongly related to cardiometabolic risk.]] | |||
[[File:Sleep-150.png|thumb|right|220px|[[Sleep apnea]] can worsen cardiovascular risk; W8MD can arrange convenient [[home sleep study]] testing when appropriate.]] | |||
[[Stroke]] risk is increased by hypertension, diabetes, smoking, atrial fibrillation, obesity, sleep apnea, and atherosclerotic disease. Semaglutide’s SELECT benefit included nonfatal stroke as part of the composite endpoint.<ref name="SELECT" /> | [[Stroke]] risk is increased by hypertension, diabetes, smoking, atrial fibrillation, obesity, sleep apnea, and atherosclerotic disease. Semaglutide’s SELECT benefit included nonfatal stroke as part of the composite endpoint.<ref name="SELECT" /> | ||